Related Experiment Video
Updated: Sep 16, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Arthi Palani1, Sagar Patel2, Shriya Patel2
1Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA. aap238@njms.rutgers.edu.
Cardiovascular Drugs and Therapy
|July 10, 2025
Summary
New diabetes drugs, glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i), offer cardiovascular benefits. Guidelines suggest starting these alongside insulin tapering for type 2 diabetes patients with cardiovascular disease.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Medicine
- Pharmacology
Background:
- Type 2 diabetes management often involves insulin therapy.
- Cardiovascular disease is a major complication in type 2 diabetes.
- Emerging diabetes medications offer significant cardiovascular benefits.
Purpose of the Study:
- To review current trials on GLP1-RA and SGLT2-i.
- To provide guidance on managing these agents with insulin.
- To introduce the concept of "de-insulinization".
Main Methods:
- Systematic review of contemporary clinical trials.
- Analysis of evidence for GLP1-RA and SGLT2-i efficacy.
- Guideline development for medication management and insulin tapering.
Main Results:
- GLP1-RA and SGLT2-i are key for cardiovascular risk reduction in type 2 diabetes.
- These agents should be initiated, with concurrent insulin tapering, for patients with cardiovascular disease.
- Individualized therapy selection is crucial, prioritizing patients with comorbidities.
Conclusions:
- GLP1-RA and SGLT2-i represent a paradigm shift in managing type 2 diabetes with cardiovascular disease.
- A systematic approach to "de-insulinization" is recommended.
- Personalized treatment strategies are essential for optimal patient outcomes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
01:23Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
01:06Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
01:16Insulin: Dosing Regimen and Adverse Effects
265
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
265
01:15Diabetes: Management and Pharmacotherapy
408
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
408